Emerging synthetic drugs for the treatment of diffuse large B-cell lymphoma
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging synthetic drugs for the treatment of diffuse large B-cell lymphoma
Authors
Keywords
-
Journal
EXPERT OPINION ON EMERGING DRUGS
Volume 28, Issue 3, Pages 181-190
Publisher
Informa UK Limited
Online
2023-08-31
DOI
10.1080/14728214.2023.2250722
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors
- (2023) Francesca Guidetti et al. Journal of Clinical Medicine
- Lenalidomide maintenance following high‐dose therapy and autologous haematopoietic stem cell transplantation in chemo‐resistant or high‐risk non‐Hodgkin lymphoma: A phase I/II study
- (2023) Julie M. Vose et al. BRITISH JOURNAL OF HAEMATOLOGY
- OPEN‐LABEL PHASE 1/2 STUDY OF CC‐99282, A CEREBLON E3 LIGASE MODULATOR (CELMOD) AGENT ± RITUXIMAB, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL)
- (2023) J. M. Michot et al. HEMATOLOGICAL ONCOLOGY
- Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)
- (2022) Warren Fiskus et al. Blood Cancer Journal
- Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study
- (2022) Gareth P. Gregory et al. Blood Advances
- Unmasking the suppressed immunopeptidome of EZH2 mutated diffuse large B-cell lymphomas with combination drug treatment
- (2022) Christopher M Bourne et al. Blood Advances
- Targeting cereblon in hematologic malignancies
- (2022) Ota Fuchs BLOOD REVIEWS
- Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
- (2022) Manali Kamdar et al. LANCET
- Kinase Dead BTK Mutations Confer Resistance to Covalent and Noncovalent BTK Inhibitors but Are Susceptible to Clinical Stage BTK Degraders
- (2022) Skye Montoya et al. BLOOD
- Precision Targeting of MYD88 Mutant DLBCL Using the Novel Combination of Irakimids and BCL2 Inhibition
- (2022) Andre M. Grilo et al. BLOOD
- Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study
- (2022) David Qualls et al. BLOOD
- First in Human (FIH) Study of GFH009, a Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, in Patients with Relapsed/Refractory (r/r) Hematologic Malignancies
- (2022) Junyuan Qi et al. BLOOD
- Phase 1b/2a Study of AZD4573 (CDK9i) and Acalabrutinib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Results from Dose-Escalation
- (2022) Paolo Strati et al. BLOOD
- Phase 1 Study of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- (2022) Jennifer Kimberly Lue et al. BLOOD
- Iberdomide (CC-220) Monotherapy or in Combination with an Anti-CD20 Monoclonal Antibody As Effective Therapy in Patients with Relapsed/Refractory Lymphoma: Early Results from a Phase 1/2 Study
- (2022) Catherine Thieblemont et al. BLOOD
- NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton's Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies
- (2022) Anthony R. Mato et al. BLOOD
- A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
- (2022) Mark A. Dawson et al. CLINICAL CANCER RESEARCH
- Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial
- (2022) Catherine Thieblemont et al. JOURNAL OF CLINICAL ONCOLOGY
- Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2022) Michael J. Dickinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412
- (2021) Grzegorz S. Nowakowski et al. JOURNAL OF CLINICAL ONCOLOGY
- ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma
- (2021) Grzegorz S. Nowakowski et al. JOURNAL OF CLINICAL ONCOLOGY
- Diffuse Large B-Cell Lymphoma
- (2021) Laurie H. Sehn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Achieving clinical success with BET inhibitors as anti-cancer agents
- (2021) Tatiana Shorstova et al. BRITISH JOURNAL OF CANCER
- Targeting CDK9 for Anti-Cancer Therapeutics
- (2021) Ranadip Mandal et al. Cancers
- Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma
- (2021) Johannes Duell et al. HAEMATOLOGICA
- Nx-5948, a Selective Degrader of BTK with Activity in Preclinical Models of Hematologic and Brain Malignancies
- (2021) Daniel W Robbins et al. BLOOD
- NIMBLE: A Phase I/II Study of AZD0466 Monotherapy or in Combination in Patients with Advanced Hematological Malignancies
- (2021) Marina Konopleva et al. BLOOD
- Combination Therapy of Bcl-2/X L dual Inhibitor AZD0466 with Acalabrutinib to Overcome Therapeutic Resistance in Aggressive R/R Mantle Cell Lymphoma
- (2021) Yijing Li et al. BLOOD
- Dual Targeting of EZH2 and HDAC with Tazemetostat and Belinostat Promotes Immunogenicity in GC-DLBCL
- (2021) Edd C Ricker et al. BLOOD
- Novel Irreversible Menin Inhibitor, BMF-219, Shows Potent Single Agent Activity in Clinically Relevant DLBCL Cells
- (2021) Priyanka Somanath et al. BLOOD
- Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701
- (2021) Jeremy S. Abramson et al. BLOOD
- Differential Effects of Iberdomide Versus Revlimid on Leukocyte Trafficking, Immune Activation and DLBCL Tumor Cell Killing
- (2021) Yumi Nakayama et al. BLOOD
- A First-in-Class STAT3 Degrader KT-333 in Development for Treatment of Hematologic Cancers
- (2021) Phillip CC Liu et al. BLOOD
- Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL
- (2021) Wyndham H. Wilson et al. CANCER CELL
- IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies
- (2021) Joshua Bennett et al. CURRENT OPINION IN HEMATOLOGY
- Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
- (2021) Frederick L. Locke et al. NEW ENGLAND JOURNAL OF MEDICINE
- Avadomide monotherapy in relapsed/refractory DLBCL: Safety, efficacy, and a predictive gene classifier
- (2020) Cecilia Carpio et al. BLOOD
- Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report
- (2020) Stuart E. Lacy et al. BLOOD
- Revving the CAR – Combination strategies to enhance CAR T cell effectiveness
- (2020) Rajat Bansal et al. BLOOD REVIEWS
- A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications
- (2020) George W. Wright et al. CANCER CELL
- Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
- (2020) Gilles Salles et al. LANCET ONCOLOGY
- BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression
- (2020) Thomas E. C. Cummin et al. Blood Advances
- A phase II study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma
- (2020) Franck Morschhauser et al. BLOOD
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- (2020) Jeremy S Abramson et al. LANCET
- Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes
- (2020) Hanna Scholze et al. Blood Advances
- Genetic and epigenetic determinants of diffuse large B-cell lymphoma
- (2020) Tanner J. Bakhshi et al. Blood Cancer Journal
- Therapeutic development and current uses of BCL-2 inhibition
- (2020) Andrew W. Roberts Hematology-American Society of Hematology Education Program
- AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
- (2019) John P. Leonard et al. JOURNAL OF CLINICAL ONCOLOGY
- IMiDs New and Old
- (2019) Samuel Yamshon et al. Current Hematologic Malignancy Reports
- Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis
- (2019) Christopher Melani et al. BLOOD
- A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies
- (2019) Darren C. Phillips et al. LEUKEMIA
- Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
- (2018) Bjoern Chapuy et al. NATURE MEDICINE
- Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
- (2018) Roland Schmitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
- (2018) Martin JS Dyer et al. JOURNAL OF CLINICAL ONCOLOGY
- Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
- (2018) Franck Morschhauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
- (2017) Catherine Thieblemont et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- (2017) Matthew S. Davids et al. JOURNAL OF CLINICAL ONCOLOGY
- A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos
- (2017) Mary E. Matyskiela et al. JOURNAL OF MEDICINAL CHEMISTRY
- Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6
- (2017) Nina Kerres et al. Cell Reports
- CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL
- (2015) P. R. Hagner et al. BLOOD
- Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs
- (2014) Philip P Chamberlain et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma
- (2014) Joydeep Bhadury et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial
- (2013) M Wang et al. LEUKEMIA
- Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
- (2012) Yibin Yang et al. CANCER CELL
- An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
- (2011) T. E. Witzig et al. ANNALS OF ONCOLOGY
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
- (2010) R. Eric Davis et al. NATURE
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search